- Austria (Website)
- Czech Republic (Website)
- Denmark (Website)
- Finland (Website)
- France (Website)
- Germany (Website)
- Italy (Website)
- Ivory Coast
bioMérieux – First-Half 2018 Results06 September, 2018
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2018. The statements had been reviewed by the Statutory Auditors.
- Strong sales dynamic, with sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
- €1,169 million in sales
- Up 3.1% as reported
- Contributive operating income before non-recurring items up 7% to €185 million, or 15.8% of sales
- 2018 financial targets revised:
- Organic growth in sales of around 9.5%, at constant exchange rates and scope of consolidation
- Contributive operating income before non-recurring items of between €340 million and€350 million
Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux performed well in the first half of the year, combining solid organic sales growth and a sharp increase in earnings. Given this momentum, we are now in a position to revise our full-year financial objectives upward while continuing our ambitious investments in innovation and in bioMérieux’s future development, to best serve our clients, patients and our public health mission."
In light of the robust organic growth reported in the first half, bioMérieux is now targeting organic sales growth for the full year of around 9.5%.
Given the good performance in the first half and the revised target for full-year organic sales growth, bioMérieux is now aiming to deliver full-year contributive operating income before non-recurring items of between €340 million and €350 million at current exchange rates. This new target takes into account the additional expense related to the acquisition of Astute Medical Inc. and the Group’s ongoing efforts in sales and innovation as part of a long-term strategy, and is based on current exchange rates.
A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 150 countries through 43 subsidiaries and a large network of distributors. In 2017, revenues reached €2.3 billion, with over 90% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP ).
Tel.: +33 (0)4 78 87 22 37
Tel.: +33 (0)4 78 87 54 75
Tel.: +33 (0)1 53 70 74 64
Tel.: +33 (0)1 53 70 74 48
Download the Full Press Release: